In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Blood Therapeutics Inc.

www.gbt.com

Latest From Global Blood Therapeutics Inc.

Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness

Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.

Financing Deals

US Product Launches To Plan For In 2020

A sizeable group of key late-stage products have the potential to reach the US market in 2020, according to a recent report from Informa’s Biomedtracker. Pharmaceutical and biotech executives will have to be on their A-game to integrate the new wave of products into patient-centric and market access-friendly commercial strategies.

 

Approvals Market Intelligence

Finance Watch: Moderna Launches Biggest Biopharma IPO Ever As US Market Resets Expectations

Public Company Edition: Moderna's $604m IPO launches as the US stock market is in decline and public biotechs are doing especially poorly. Also, as Shire acquisition closing moves near, Takeda firms up additional financing; and Global Blood, Theravance, Amarin capitalize on good news.

Financing Business Strategies

Global Blood Therapeutics Leaves ASH With Momentum Behind Voxelotor In Sickle Cell Disease

Company revealed that US FDA agreed to accelerated approval pathway for voxelotor in sickle cell disease, with focus on stroke prevention. Updated data from a key trial was also released at ASH.

Clinical Trials Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Global Blood Therapeutics Inc.
  • Senior Management
  • Ted W Love, MD, Pres. & CEO
    Jeffrey Farrow, CFO
    Jung E Choi, Chief Bus. & Strategy Officer
    David L Johnson, Chief Commercial Officer
    Brian Cathers, PhD, CSO
  • Contact Info
  • Global Blood Therapeutics Inc.
    Phone: (650) 741-7700
    171 Oyster Point Blvd.
    Ste. 300
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register